These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37686586)

  • 41. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.
    Aiken TJ; Erbe AK; Zebertavage L; Komjathy D; Feils AS; Rodriguez M; Stuckwisch A; Gillies SD; Morris ZS; Birstler J; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
    Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
    Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Gang M; Marin ND; Wong P; Neal CC; Marsala L; Foster M; Schappe T; Meng W; Tran J; Schaettler M; Davila M; Gao F; Cashen AF; Bartlett NL; Mehta-Shah N; Kahl BS; Kim MY; Cooper ML; DiPersio JF; Berrien-Elliott MM; Fehniger TA
    Blood; 2020 Nov; 136(20):2308-2318. PubMed ID: 32614951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
    Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
    Front Immunol; 2021; 12():751138. PubMed ID: 34804035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.
    Fabian KP; Hodge JW
    Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.
    Seay K; Church C; Zheng JH; Deneroff K; Ochsenbauer C; Kappes JC; Liu B; Jeng EK; Wong HC; Goldstein H
    J Virol; 2015 Jun; 89(12):6264-74. PubMed ID: 25833053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
    Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
    J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
    Yu L; Huang L; Lin D; Lai X; Wu L; Liao X; Liu J; Zeng Y; Liang L; Zhang G; Wang B; Wu Z; Tao S; Liu Y; Jiao C; Chang LJ; Yang L
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2643-2652. PubMed ID: 34724115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
    Bashiri Dezfouli A; Yazdi M; Benmebarek MR; Schwab M; Michaelides S; Miccichè A; Geerts D; Stangl S; Klapproth S; Wagner E; Kobold S; Multhoff G
    Front Immunol; 2022; 13():883694. PubMed ID: 35720311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
    Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
    Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
    Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
    Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
    [No Abstract]   [Full Text] [Related]  

  • 60. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.